Medigene extends cancer immunotherapy alliance with bluebird bio
Category: #health  By Dhananjay Punekar  Date: 2018-05-16
  • share
  • Twitter
  • Facebook
  • LinkedIn

Medigene extends cancer immunotherapy alliance with bluebird bio

Medigene AG, a Germany-based biotech firm, and bluebird bio Inc., have reportedly decided to extend their collaboration over cancer immunotherapy. The strategic move may plausibly be aimed at producing a revenue of over USD 509 million for Medigene.

Reportedly, both the firms have decided to increase the number of target antigens/major histocompatibility complex restriction combinations from four to six for the discovery of particular TCR lead candidates. Sources also claimed that the partnership is targeted toward the development of two more TCR-T cancer treatments.

Celgene Corporation, a U.S. based biotech firm, has agreed to shell out a one-time installment of USD 8 million to Medigene. It has been speculated that Celgene will pay nearly up to USD 250 million in terms of milestone payments for two novel TCR ventures. As per reliable sources, Celgene Corp. is also expected to pay double-digit tiered royalties on the net sales of these successful TCR programs.

If reports are to be relied on, the deal between Medigen & bluebird bio Inc., which was estimated at over USD 1 billion in 2016, will help in the integration of Medigen’s TCR isolation & characterization platform with bluebird bio’s manufacturing, lentiviral vector, synthetic biology, and gene-editing proficiencies. Experts familiar with the matter have claimed that TCR tool developed by Medigene AG has been designed to alter T-cells of the cancer patient with tumor-specific TCRs, thereby generating cells that would be able to aptly identify and destroy cancer tumor cells.

As per the terms & conditions stated in the agreement, bluebird bio has taken the responsibility for preclinical as well as clinical growth & commercialization of TCR-T candidates. In return, the company is likely to acquire a license for the specific TCRs patents. Some of the key officials of Medigene have stated that EBITDA guidance, revenue, and R&D funding will remain unaltered though the agreement is extended.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...